INTENSITY THERAPEUTICS

Company snapshot

Intensity Therapeutics is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. We leverage our DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Our lead product candidate, INT230-6, is currently being evaluated i

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for INTENSITY THERAPEUTICS. Not investment advice.

• Peer + 0 momentum

  BEONE MEDICINES AUS

  TA overlap score 40

• Peer + 0 momentum

  PUMA BIOTECHNOLOGY

  TA overlap score 28

• Peer + 0 momentum

  Prelude Therapeutics

  TA overlap score 22.6

Recent activity

Latest pipeline, patent, and corporate events for INTENSITY THERAPEUTICS.

1. Jun 8, 2026 Clinical update

   IT-03 — Phase 3

2. May 23, 2026 Clinical update

   INT230-6 — Phase 3

3. May 23, 2026 Clinical update

   INT230-6 — Phase 2

4. May 23, 2026 Clinical update

   JIN-A02 — Phase 2

5. May 23, 2026 Clinical update

   MPT0B640 — Phase 1

View all clinical trial activity →

• What is INTENSITY THERAPEUTICS?

  Intensity Therapeutics is a biotech organization headquartered in Shelton, USA. It trades on NYSE under ticker INTS. Primary therapeutic focus areas include Breast Cancer, Sarcoma,Soft Tissue, EGFR Mutant Advanced Non-small Cell Lung Cancer, Advanced Solid Tumor, Covid19. NovaPha

• Is INTENSITY THERAPEUTICS publicly traded?

  Yes. INTENSITY THERAPEUTICS is listed with ticker INTS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does INTENSITY THERAPEUTICS develop or market?

  We link 9 drug profile(s) where INTENSITY THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/intensity-therapeutics-inc#company-drugs.

• What are the latest developments for INTENSITY THERAPEUTICS?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does INTENSITY THERAPEUTICS focus on?

  INTENSITY THERAPEUTICS focuses on Breast Cancer, Sarcoma,Soft Tissue, EGFR Mutant Advanced Non-small Cell Lung Cancer based on our analysis of their pipeline programs and drug development activities.